Furthermore, as M1 TAMs have been reported to be associated with improved survival in HER2+ breast cancer [20,22], combining therapies targeting the immunosuppressive microenvironment, e.g., macrophage polarization towards the M1 phenotype, with anti-HER2 treatments could be a beneficial treatment strategy in HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.